Details of the Drug

General Information of Drug (ID: DMISPYI)

Drug Name
GRN-300
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 1 [1]
Drug Type
Small molecule
Cross-matching ID
TTD ID
D40NQW

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Salt-inducible kinase 2 (SIK2) TTCUGZR SIK2_HUMAN Inhibitor [2]
SIK family kinase 3 (SIK3) TTW6L4V SIK3_HUMAN Inhibitor [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04711161) Ph 1/1B Evaluation of the Safety, Pharmacokinetics and Efficacy of GRN-300, a Salt-inducible Kinase Inhibitor, Alone and in Combination With Paclitaxel, in Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Green3Bio